A Phase 3 interventional study of Leuprolide acetate - Formulation A and Leuprolide acetate - Formulation B in Prostate Cancer, sponsored by Abbott. Completed at 63 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-19.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 10th largest by enrollment of the 69 interventional ones that give a count, is one of 3 that started in 2008, is one of 26 in phase 3, and was the 16th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Ontario Clinical Oncology Group (OCOG) · Sites in Canada
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 27 · Phase 4 9
First in 1994; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 310 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 77 across the 69 interventional studies. Of the 47 that completed or were terminated, 26 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 70 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
12 studies in Prostatic Neoplasms by Abbott: none open now, none under way, none of them phase 3. Of 12 finished, 3 (25%) have results posted.
Among the 12 studies in Prostatic Neoplasms by Abbott, this one is one of 2 that started in 2008, is one of 4 in phase 3, and was the 7th registered.
Abbott’s Prostatic Neoplasms studies by the year they started, since 2001.
7 of the studies testing leuprolide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05169112Phase 3Ottawa Hospital Research InstituteImpact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | 2026-11 |
| NCT04302454Phase 3University Medical Center GroningenAndrogen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy | 2027-10-21 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT04249154McGill University Health Centre/Research Institute of the McGill University Health CentrePostop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer | 2026-12-15 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, from their registry updates:
Among Abbott’s 12 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the efficacy and safety of 2 new formulations of leuprolide acetate 45 mg 6-month depot, Formulation A or Formulation B, for the treatment of patients with prostate cancer. A formulation will be deemed successful if the percentage of subjects with suppression of testosterone to \<= 50 ng/dL from Week 4 to Week 48 is not less than 87%, (the lower bound of the 2-sided 90% confidence interval), a protocol-specified criterion.
A total of 300 male subjects were planned to be enrolled. Subjects were to receive a total of 2 intramuscular (IM) injections of the same formulation, either Formulation A or Formulation B, administered 24 weeks apart. The first 150 subjects were to receive Formulation A for both injections and the next 150 subjects were to receive Formulation B for both injections. The sponsor was to conduct an ongoing review of the primary endpoint data (suppression of testosterone \<= 50 ng/dL) and planned to stop enrollment of Formulation A or Formulation B, or not to administer the second injection of Formulation A or Formulation B, if 15 or more subjects did not achieve testosterone suppression by Week 4 or failed to maintain testosterone suppression during the treatment period.
All analyses and summaries were to be conducted separately for subjects who received Formulation A or Formulation B.
This study was to be conducted at approximately 60-80 investigative sites. Subjects participated in the trial for approximately 14 months.
This trial was to include a Screening Period (up to 4 weeks), a 12-month Treatment Period (two 6-month treatment cycles), and a Follow-Up Period (30 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-confirmed prostatic adenocarcinoma in Jewett Clinical Stage A2, B, C or D and TNM* classification cT1b-4, N: any, M: any.
*Tumor/Nodes/
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leuprolide acetate 45 mg, 6-month depot
Drug: Leuprolide acetate - Formulation A
Leuprolide acetate, 45 mg, 6-month depot
Drug: Leuprolide acetate - Formulation B
Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
Also known as: Lupron, leuprorelin, gonadotropin hormone-releasing hormone (GnRH), luteinizing hormone-releasing hormone (LHRH)
Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
Also known as: Lupron, leuprorelin, gonadotropin hormone-releasing hormone (GnRH), luteinizing hormone-releasing hormone (LHRH)
Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint.
The percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.
Time frame: Week 4 to Week 48
Adjusted Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: ITT Population for the Primary Endpoint Adjusted
The adjusted percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. The primary efficacy analysis was adjusted to censor subjects who received an anti-androgen at the last testosterone measurement before use of the anti-androgen. One additional subject was censored because of a laboratory error, at the last measurement before the error. The adjusted 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.
Time frame: Week 4 to Week 48
Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation B: ITT Population for the Primary Endpoint Preplanned
The percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.
Time frame: Week 4 to Week 48
Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation A: ITT Population
Baseline was the last measurement before the first dose of Formulation A. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.
Time frame: Baseline, Days 2 and 8, Weeks 2, 4, 8, 14, 20, 24, 26, 30, 34, 40, 46, 48, and Final Visit
Mean Testosterone Concentration (+/- Standard Error) at Each Visit for Formulation B: ITT Population
Baseline was the last measurement before the first dose of Formulation B. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.
Time frame: Baseline, Days 2 and 8, Weeks 2, 4, 8, 14, 20, 24, 26, 30, 34, 40, 46, 48, and Final Visit
Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation A: ITT Population
The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.
Time frame: Week 24 before the second injection until 2 weeks after Week 24 (2 hours [h], 4 h, 8 h, 1 day [d], 2 d, 3-10 d, and 11-17 d postdose)
Mean (+/- Standard Error) Acute-on-chronic Changes in Testosterone From Pre-injection Levels for Formulation B: ITT Population
The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.
Time frame: Week 24 before the second injection until 2 weeks after Week 24 (2 h, 4 h, 8 h, 1 d, 2 d, 3-10 d, and 11-17 d postdose)
Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation A: ITT Population
The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.
Time frame: Week 24 before the second injection until 2 weeks after Week 24 (2 h, 4 h, 8 h, 1 d, 2 d, 3-10 d, and 11-17 d postdose)
Mean (+/- Standard Error) Acute-on-chronic Changes in Luteinizing Hormone From Pre-injection Levels for Formulation B: ITT Population
The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.
Time frame: Week 24 before the second injection until 2 weeks after Week 24 (2 h, 4 h, 8 h, 1 d, 2 d, 3-10 d, and 11-17 d postdose)
Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation A: ITT Population
PSA levels were measured at baseline and each treatment visit for Formulation A. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.
Time frame: Baseline, Day 8, Week 14, Week 24, Week 30, Week 40, Week 48, and the Final Visit
Mean (+/- Standard Error) Prostate Specific Antigen (PSA) at Baseline, Visits Throughout the Study, and at Final Visit for Formulation B: ITT Population
PSA levels were measured at baseline and each treatment visit for Formulation B. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.
Time frame: Baseline, Day 8, Week 14, Week 24, Week 30, Week 40, Week 48, and the Final Visit
The enrollment of subjects with Formulation A occurred sequentially before the enrollment of subjects with Formulation B.
| Milestone | Leuprolide Acetate - Formulation A | Leuprolide Acetate - Formulation B |
|---|---|---|
| Started | 151 | 159 |
| Completed | 134 | 114 |
| Not completed | 17 | 45 |
The percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.
| Percent Suppressed | Leuprolide Acetate - Formulation A |
|---|---|
| Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary Endpoint. | 93.6 ± 2.05 |
Baseline was the last measurement before the first dose of Formulation A. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.
| ng/dL | Leuprolide Acetate - Formulation A |
|---|---|
| Testosterone concentration at baseline | 432.9 ± 14.35 |
| Testosterone concentration at Day 2 | 613.1 ± 21.53 |
| Testosterone concentration at Day 8 | 468.2 ± 16.55 |
| Testosterone concentration at Week 2 | 127.1 ± 7.36 |
| Testosterone concentration at Week 4 | 16.0 ± 0.70 |
| Testosterone concentration at Week 8 | 9.6 ± 0.46 |
| Testosterone concentration at Week 14 | 9.2 ± 0.46 |
| Testosterone concentration at Week 20 | 8.5 ± 0.46 |
| Testosterone concentration at Week 24 | 14.3 ± 1.25 |
| Testosterone concentration at Week 26 | 9.0 ± 0.47 |
| Testosterone concentration at Week 30 | 9.9 ± 1.67 |
| Testosterone concentration at Week 34 | 13.0 ± 4.14 |
| Testosterone concentration at Week 40 | 8.8 ± 0.41 |
| Testosterone concentration at Week 46 | 8.8 ± 0.46 |
| Testosterone concentration at Week 48/Final Visit | 13.3 ± 3.67 |
Baseline was the last measurement before the first dose of Formulation B. The mean +/- standard error was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.
| ng/dL | Leuprolide Acetate - Formulation B |
|---|---|
| Testosterone concentration at baseline | 414.0 ± 14.15 |
| Testosterone concentration at Day 2 | 578.0 ± 20.14 |
| Testosterone concentration at Day 8 | 466.9 ± 17.70 |
| Testosterone concentration at Week 2 | 127.4 ± 7.35 |
| Testosterone concentration at Week 4 | 15.3 ± 0.71 |
| Testosterone concentration at Week 8 | 9.1 ± 0.44 |
| Testosterone concentration at Week 14 | 8.9 ± 0.42 |
| Testosterone concentration at Week 20 | 9.6 ± 0.54 |
| Testosterone concentration at Week 24 | 28.0 ± 3.97 |
| Testosterone concentration at Week 26 | 15.6 ± 2.63 |
| Testosterone concentration at Week 30 | 9.4 ± 0.60 |
| Testosterone concentration at Week 34 | 9.7 ± 0.53 |
| Testosterone concentration at Week 40 | 9.5 ± 0.52 |
| Testosterone concentration at Week 46 | 9.4 ± 0.64 |
| Testosterone concentration at Week 48/Final Visit | 13.8 ± 1.87 |
The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.
| ng/dL | Leuprolide Acetate - Formulation A |
|---|---|
| Testosterone concentration at 2 hours postdose | -1.9 ± 0.85 |
| Testosterone concentration at 4 hours postdose | -1.2 ± 0.93 |
| Testosterone concentration at 8 hours postdose | -1.3 ± 1.02 |
| Testosterone concentration at Day 1 postdose | -0.1 ± 0.95 |
| Testosterone concentration at Day 2 postdose | -0.1 ± 0.92 |
| Testosterone concentration at Days 3-10 postdose | -1.0 ± 0.89 |
| Testosterone concentration at Days 11-17 postdose | -2.1 ± 0.87 |
The acute-on-chronic effect is an agonistic stimulation of serum testosterone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.
| ng/dL | Leuprolide Acetate - Formulation B |
|---|---|
| Testosterone concentration at 2 hours postdose | -0.7 ± 0.66 |
| Testosterone concentration at 4 hours postdose | 1.6 ± 1.13 |
| Testosterone concentration at 8 hours postdose | 3.6 ± 1.35 |
| Testosterone concentration at Day 1 postdose | 8.0 ± 1.80 |
| Testosterone concentration at Day 2 postdose | 7.8 ± 1.81 |
| Testosterone concentration at Days 3-10 postdose | 4.5 ± 1.07 |
| Testosterone concentration at Day 11-17 postdose | -4.2 ± 1.43 |
The adjusted percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. The primary efficacy analysis was adjusted to censor subjects who received an anti-androgen at the last testosterone measurement before use of the anti-androgen. One additional subject was censored because of a laboratory error, at the last measurement before the error. The adjusted 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.
| Percent Suppressed | Leuprolide Acetate - Formulation A |
|---|---|
| Adjusted Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: ITT Population for the Primary Endpoint Adjusted | 93.4 (89.9 to 96.9) |
The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation A. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.
| ng/dL | Leuprolide Acetate - Formulation A |
|---|---|
| Testosterone concentration at 2 hours postdose | 0.2 ± 0.03 |
| Testosterone concentration at 4 hours postdose | 0.2 ± 0.03 |
| Testosterone concentration at 8 hours postdose | 0.2 ± 0.02 |
| Testosterone concentration at Day 1 postdose | 0.2 ± 0.02 |
| Testosterone concentration at Day 2 postdose | 0.1 ± 0.01 |
| Testosterone concentration at Days 3-10 postdose | 0.1 ± 0.01 |
| Testosterone concentration at Days 11-17 postdose | 0.1 ± 0.02 |
The acute-on-chronic effect is an agonistic stimulation of luteinizing hormone after the second depot injection of Formulation B. The mean +/- standard error changes were measured to assess this effect from just before to 2 weeks after the second injection.
| ng/dL | Leuprolide Acetate - Formulation B |
|---|---|
| Testosterone concentration at 2 hours postdose | 0.4 ± 0.07 |
| Testosterone concentration at 4 hours postdose | 0.5 ± 0.12 |
| Testosterone concentration at 8 hours postdose | 0.4 ± 0.11 |
| Testosterone concentration at Day 1 postdose | 0.4 ± 0.08 |
| Testosterone concentration at Day 2 postdose | 0.2 ± 0.04 |
| Testosterone concentration at Days 3-10 postdose | 0.1 ± 0.02 |
| Testosterone concentration at Days 11-17 postdose | -0.1 ± 0.04 |
PSA levels were measured at baseline and each treatment visit for Formulation A. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.
| ng/mL | Leuprolide Acetate - Formulation A |
|---|---|
| PSA concentration at baseline | 35.0 ± 11.21 |
| PSA Concentration at Day 8 | 40.4 ± 12.90 |
| PSA Concentration at Week 14 | 2.4 ± 0.62 |
| PSA Concentration at Week 24 | 2.9 ± 1.09 |
| PSA Concentration at Week 30 | 1.6 ± 0.46 |
| PSA Concentration at Week 40 | 2.2 ± 0.82 |
| PSA Concentration at Week 48/Final Visit | 3.7 ± 1.51 |
PSA levels were measured at baseline and each treatment visit for Formulation B. The mean (+/- standard error) was calculated at each visit. The final visit occurred at Week 48 unless the subject prematurely discontinued the study.
| ng/mL | Leuprolide Acetate - Formulation B |
|---|---|
| PSA concentration at baseline | 20.5 ± 3.88 |
| PSA Concentration at Day 8 | 23.1 ± 4.03 |
| PSA Concentration at Week 14 | 2.4 ± 0.51 |
| PSA Concentration at Week 24 | 2.5 ± 0.65 |
| PSA Concentration at Week 30 | 2.7 ± 0.86 |
| PSA Concentration at Week 40 | 2.5 ± 0.85 |
| PSA Concentration at Week 48/Final Visit | 6.2 ± 2.75 |
The percentage of subjects with testosterone suppression (\<= 50 ng/dL) from Week 4 to Week 48 was calculated by the Kaplan-Meier method for right-censored observations. Subjects who failed testosterone suppression were considered failures on the first day of a testosterone measurement (\>50 ng/dL). Subjects who prematurely discontinued without escaping and those who were successfully suppressed through Week 48 were censored at their last measured testosterone value (Day 337 to Day 340 at Week 48). The 90% 2-sided confidence interval was calculated from Kaplan-Meier estimates.
| Percent suppressed | Leuprolide Acetate - Formulation B |
|---|---|
| Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation B: ITT Population for the Primary Endpoint Preplanned | 86.9 (82.2 to 91.7) |
Collected over Both serious adverse events and adverse events were reported from the receipt of the first dose of study drug through the 30-day follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leuprolide Acetate - Formulation A | — | 31/151 (20.5%) | 133/151 (88.1%) |
| Leuprolide Acetate - Formulation B | — | 41/159 (25.8%) | 127/159 (79.9%) |
| Event | Leuprolide Acetate - Formulation A | Leuprolide Acetate - Formulation B |
|---|---|---|
| coronary artery diseaseCardiac disorders | 3/151 | 2/159 |
| chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 3/151 | 0/159 |
| cardiac failure congestiveCardiac disorders | 2/151 | 3/159 |
| pneumoniaInfections and infestations | 2/151 | 3/159 |
| syncopeNervous system disorders | 0/151 | 3/159 |
| anemiaBlood and lymphatic system disorders | 2/151 | 0/159 |
| atrial fibrillationCardiac disorders | 2/151 | 0/159 |
| carotid artery stenosisNervous system disorders | 2/151 | 0/159 |
| transient ischemic attackNervous system disorders | 2/151 | 0/159 |
| cholelithiasisHepatobiliary disorders | 2/151 | 0/159 |
| Event | Leuprolide Acetate - Formulation A | Leuprolide Acetate - Formulation B |
|---|---|---|
| hot flushVascular disorders | 88/151 | 71/159 |
| injection site painGeneral disorders | 27/151 | 26/159 |
| arthralgiaMusculoskeletal and connective tissue disorders | 13/151 | 22/159 |
| fatigueGeneral disorders | 18/151 | 14/159 |
| constipationGastrointestinal disorders | 15/151 | 16/159 |
| nasopharyngitisInfections and infestations | 10/151 | 15/159 |
| dizzinessNervous system disorders | 8/151 | 15/159 |
| hypertensionVascular disorders | 9/151 | 15/159 |
| insomniaPsychiatric disorders | 13/151 | 9/159 |
| headacheNervous system disorders | 11/151 | 9/159 |
| Age, Categorical(Participants) | Leuprolide Acetate - Formulation A | Leuprolide Acetate - Formulation B | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 33 | 51 |
| >=65 years | 133 | 126 | 259 |
| Sex: Female, Male(Participants) | Leuprolide Acetate - Formulation A | Leuprolide Acetate - Formulation B | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 151 | 159 | 310 |
| Region of Enrollment(participants) | Leuprolide Acetate - Formulation A | Leuprolide Acetate - Formulation B | Total |
|---|---|---|---|
| United States | 151 | 159 | 310 |
The record gives a start of Feb 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide